Pharma Marketing News
PMN Home | Advertising Information | FAQs
About Us | Contact Us | Privacy Policy
Subscribe Glossary
Pharma Marketing Blog Pharmaguy Audio Podcasts Event Calendar PReader Surveys

Share |

2014 Was a Good Year for FDA & Pharma
Banging Year for Drug Approvals, Wimpy Year for Enforcement Actions

Bang and WhimperThe U.S. Food and Drug Administration (FDA) ended 2014 with a bang and a whimper.

The Agency approved a total of 41 new molecular entities (NMEs) and biologics (BLAs) in 2014, the greatest number since 1996. That was the bang. FDA, however, also ended the year with a whimper. The Agency sent out only a meager 10 advertising enforcement letters in 2014, the fewest ever.

There may be a single explanation for both phenomena: the Prescription Drug User Fee Act (PDUFA) payments to FDA from pharma. These payments now account for more than 65% of FDA's budget for the approval and regulation of drugs.

Topics (partial list):
  • Orphan Drugs Are "Where the Money Is"
  • Banging Drug Prices
  • Wimpy Enforcement
  • Busy, Busy FDA
  • PDUFA Fees vs. Enforcement
Download the full article (PDF file) here:

Issue: Vol. 14, No. 2: January 2015

Find other articles in related Topic Areas:

Vol 14, #1 Contents

Contact Information
Pharma Marketing News

Pharma Marketing News | Subscribe | Industry Insights | Podcasts | Pharmaguy | Blog
Surveys | Glossary | Conference Calendar | Advertising Information | FAQs | About Us | Privacy Policy

© 2015. Pharma Marketing Network. All rights reserved.